Retroperitoneal sarcoma was treated in 32 patients in 1970-1986. The dominant initial symptom was pain (63%) and the most common clinical finding was a palpable mass (75%). Primary radical resection was possible in 16 cases, but the tumor recurred in 14 after 3-33 months. Repeated radical or palliative surgery was possible in most patients, with altogether 57 tumor resections in 23 patients. The postoperative mortality was 3.5%. The cumulative 5-year survival rate was 28%, but when the primary resection was radical the figure rose to 46%. Periodic computed tomographic scanning and an aggressive surgical approach in recurrence of tumor can be expected to enhance the prognosis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Primary bronchial leiomyosarcoma: a diagnostic challenge.
BMC Pulm Med
January 2025
Department of Pathology, Affiliated Hospital of Zunyi Medical University, Zunyi City, Guizhou Province, P.R. China.
Background: Pulmonary bronchial leiomyosarcoma is an extremely rare malignant tumour of the lung originating from the mesenchymal tissue. The retroperitoneal region is the most common site of leiomyosarcoma. It exhibits a high degree of malignancy and a poor prognosis, thereby highlighting the significance of early diagnosis of this disease.
View Article and Find Full Text PDFPreoperative radiotherapy combined with surgery versus surgery alone for primary retroperitoneal sarcoma: a meta-analysis.
Sci Rep
January 2025
Department of Neurosurgery, Seoul National University Hospital, 101 Daehak-ro, Jongro-gu, 03080, Seoul, South Korea.
The efficacy of preoperative radiotherapy combined with surgery (preRT + S) for primary retroperitoneal sarcoma (RPS) remains unclear. This study aimed to compare preRT + S with surgery alone (SA) in patients with RPS. Core databases were searched for directly comparative studies depending on preRT.
View Article and Find Full Text PDFExtraskeletal Ewing sarcoma with uterine cornua attachment mimicking high grade endometrial stromal sarcoma: A case report and brief literature review.
Gynecol Oncol Rep
December 2024
Department of Pathology, University of California San Diego, La Jolla, CA, USA.
Background: Ewing sarcoma is an EWSR1-rearranged aggressive malignancy that occurs commonly in bone and has small round blue cell morphology. A diagnostic challenge is presented in the cases of extraskeletal Ewing sarcoma involving solid organs, such as the uterus.
Case Report And Brief Literature Review: We present the case of a 54-year-old female with a large pelvic mass connected to the uterine cornua and retroperitoneal soft tissue.
Oncogenic Functions of Alternatively Spliced Isoform in Retroperitoneal Liposarcoma.
Int J Mol Sci
December 2024
The James Comprehensive Cancer Center, Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Retroperitoneal liposarcoma (RPLPS) is one of the most common histologic subtypes of soft tissue sarcoma (STS). Complete surgical resection remains the mainstay treatment, while the high rate of locoregional recurrence constitutes the predominant cause of mortality. Well-differentiated (WDLPS) and dedifferentiated (DDLPS) liposarcoma are the most frequent subtypes of RPLPS and present amplified MDM2 gene as a hallmark.
View Article and Find Full Text PDFComparing ChatGPT-3.5 and ChatGPT-4's alignments with the German evidence-based S3 guideline for adult soft tissue sarcoma.
iScience
December 2024
Department of Surgery, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Clinical reliability assessment of large language models is necessary due to their increasing use in healthcare. This study assessed the performance of ChatGPT-3.5 and ChatGPT-4 in answering questions deducted from the German evidence-based S3 guideline for adult soft tissue sarcoma (STS).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!